Related Experiment Video
Updated: Jul 24, 2026

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
A biphasic drug-releasing microneedle with ROS scavenging and angiogenesis for the treatment of diabetic ulcers
Xinyue He1, Lianghong Peng2, Liming Zhou1
1Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Key Laboratory of Regenerative Medicine of Ministry of Education, Guangdong Provincial Engineering and Technological Research Centre for Drug Carrier Development, Department of Biomedical Engineering, Jinan University, Guangzhou 510632, China.
Abstract:
Diabetic ulcers are one of the common complications in diabetic patients. Delayed wound healing is associated with persistent pro-inflammatory M1 polarization, reduced angiogenesis and increased reactive oxygen species (ROS) in the microenvironment. Wound healing consists of multiple phases and therefore requires treatment tailored to each phase. In this study, a biphasic drug-releasing microneedle (MN) was fabricated to achieve early ROS scavenging and late accelerated angiogenesis to promote wound healing. Vascular endothelial growth factor (VEGF) was first encapsulated in methacryloylated sulfonated chitosan (SCSMA) microspheres (V@MP), and then V@MP was loaded into hyaluronic acid (HA) microneedles along with cerium dioxide nanoparticles (CONPs). Rapid dissolution of HA rapidly releases the CONPs to clear ROS, whereas the V@MP stays in the wound. SCSMA slow degradation prolongs the release of VEGF, thereby promoting angiogenesis. In vitro and in vivo studies have shown that this biphasic drug-releasing smart microneedle improves cell proliferation and migration, effectively scavenges ROS, promotes angiogenesis and tissue regeneration, and synergistically promotes M2 macrophage polarization. It provides a new delivery mode for nano-enzymes and growth factors that could be multifunctional and synergistic in the treatment of diabetic ulcers. STATEMENT OF SIGNIFICANCE: In our study, we present a microneedle (V@MP/C@MN) that can release drugs biphasically, which showed good repair ability in diabetic ulcer model. Large amounts of CONPs were rapidly released to alleviate oxidative stress during the inflammation of the wound, and V@MP stayed in the wound for a long period of time to release VEGF and promote angiogenesis in the late stage of wound healing. The results indicated that V@MP/C@MN could promote cell proliferation and migration, effectively scavenge ROS, promote angiogenesis and tissue regeneration, and synergistically promote M2 macrophage polarization, which could play a multifunctional and synergistic role in the treatment of diabetic ulcers.
Insights
This study developed a biphasic microneedle for diabetic ulcers. It releases nanoparticles to clear reactive oxygen species early and growth factors later, promoting healing and tissue regeneration.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Nanotechnology
Background:
- Diabetic ulcers exhibit delayed healing due to inflammation, oxidative stress, and poor angiogenesis.
- Current treatments often lack phase-specific delivery, hindering effective wound repair.
Purpose of the Study:
- To develop a biphasic drug-releasing microneedle system for enhanced diabetic ulcer treatment.
- To achieve early reactive oxygen species (ROS) scavenging and late-stage angiogenesis promotion.
Main Methods:
- Fabrication of hyaluronic acid microneedles loaded with cerium dioxide nanoparticles (CONPs) and vascular endothelial growth factor (VEGF)-loaded methacryloylated sulfonated chitosan (SCSMA) microspheres (V@MP).
- In vitro and in vivo evaluation of the microneedle's efficacy in ROS scavenging, angiogenesis promotion, and tissue regeneration.
Main Results:
- The microneedle system demonstrated biphasic release: rapid CONP release for ROS scavenging and sustained VEGF release from V@MP for angiogenesis.
- Significant improvement in cell proliferation, migration, ROS clearance, and M2 macrophage polarization observed.
- Effective promotion of angiogenesis and tissue regeneration in a diabetic ulcer model.
Conclusions:
- The developed biphasic microneedle (V@MP/C@MN) offers a novel, multifunctional approach for diabetic ulcer treatment.
- This system synergistically addresses key challenges in diabetic wound healing, including oxidative stress and impaired angiogenesis.
- The microneedle platform shows potential for advanced delivery of nano-enzymes and growth factors in regenerative medicine.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
07:41Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability
Published on: July 12, 2024
Related Concept Videos
Modified-Release Drug Delivery Systems: Stimuli-Activated
Oral Drug Delivery Systems: Continuous-Release Systems
Diabetic Foot Ulcer